U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07258407) titled 'A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer' on Nov. 20.
Brief Summary: This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration-Resistant Prostatic Cancer
Intervention:
DRUG: TD001
Intravenous (IV) infusion at protocol-defined doses and sch...